Abstract | BACKGROUND: The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase III, randomized, double-blind, placebo-controlled study of icatibant ( bradykinin B(2) receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH deficiency or dysfunction (type I/II). OBJECTIVE: To investigate icatibant efficacy and safety in subjects with acute HAE attacks. METHODS: Subjects with moderate to very severe cutaneous or abdominal symptoms received icatibant (n = 43) or placebo (n = 45). Five subjects with laryngeal (mild-to-moderate) first attacks received icatibant (n = 3) or placebo (n = 2), and 5 subjects with severe laryngeal first attacks received open-label icatibant. RESULTS: Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P < .001, primary endpoint), onset of primary symptom relief (1.5 vs 18.5 hours; P < .001, key secondary endpoint), or almost complete symptom relief (8.0 vs 36.0 hours; P = .012) and provided a shorter time to initial symptom relief (0.8 vs 3.5 hours; P < .001). For laryngeal attacks, median time to 50% or more reduction in symptom severity was 2.5 hours ( icatibant) and 3.2 hours (placebo). No icatibant-treated subject required rescue medication before symptom relief occurred. The incidence of adverse events (AEs) was similar in icatibant- and placebo-treated subjects (41% and 52%, respectively). All icatibant-treated subjects experienced injection site reactions, but none reported clinically relevant changes in safety parameters or serious AEs. CONCLUSIONS: FAST-3 demonstrated that icatibant was effective and generally well tolerated in subjects with acute HAE attacks. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT00912093.
|
Authors | William R Lumry, H Henry Li, Robyn J Levy, Paul C Potter, Henriette Farkas, Dumitru Moldovan, Marc Riedl, Hongbin Li, Timothy Craig, Bradley J Bloom, Avner Reshef |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 107
Issue 6
Pg. 529-37
(Dec 2011)
ISSN: 1534-4436 [Electronic] United States |
PMID | 22123383
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Bradykinin B2 Receptor Antagonists
- icatibant
- Bradykinin
|
Topics |
- Adult
- Angioedemas, Hereditary
(drug therapy)
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage)
- Bradykinin
(administration & dosage, analogs & derivatives)
- Bradykinin B2 Receptor Antagonists
- Double-Blind Method
- Female
- Humans
- Injections, Subcutaneous
- Kaplan-Meier Estimate
- Male
|